Does sacituzumab-govitecan act as a conventional antibody drug conjugate (ADC), a prodrug of SN-38 or both?
Ann Transl Med
.
2021 Jul;9(14):1113.
doi: 10.21037/atm-21-1103.
Authors
Daniel V Santi
1
,
Luc Cabel
2
,
François-Clément Bidard
2
3
Affiliations
1
Prolynx, San Francisco, CA, USA.
2
Medical Oncology, Institut Curie, Paris, France.
3
UVSQ/Paris-Saclay University, Paris, France.
PMID:
34430554
PMCID:
PMC8350658
DOI:
10.21037/atm-21-1103
No abstract available
Publication types
Editorial
Comment